RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold

A day after Biogen rattled the biopharma world with the news that its lead late-stage therapy aducanumab proved worthless in treating Alzheimer’s — a disaster that may drive a stake through the heart of the amyloid beta theory once and for all — the big biotech’s partners at Eisai have come up with their next big move.